NCT00612664CompletedPhase 2
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Bristol-Myers Squibb11 sites in 2 countries158 target enrollmentStarted: March 2008Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 158
- Locations
- 11
- Primary Endpoint
- Radiographic imaging, photographic and clinical evaluation will be used for tumor assessment to determine 6-month progression-free survival rate
Study Overview
Brief Summary
The main purpose of this study is to estimate the proportion of patients with a type of skin cancer called melanoma who are progression free, (that is, the cancer has not gotten substantially worse), when treated with Anti-CD137 (4-1BB) (BMS-663513) at 0.1 mg/kg, 1 mg/kg or 5 mg/kg every 3 weeks or 1 mg/kg every 6 weeks
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects must have been previously treated with one line of systemic anti-cancer therapy (non-experimental or experimental) for metastatic disease, and relapsed, failed to respond (CR or PR) or did not tolerate that regimen. If the treatment has been administered as an adjuvant and/or neoadjuvant therapy, the subject must have documented disease progression from the last treatment and also received one additional line of systemic therapy for metastatic disease.
- •Men and women, who are at least 18 years of age
Exclusion Criteria
- •Ocular or mucosal melanoma
- •Complete surgical resection of all identifiable sites of disease
- •Symptomatic brain metastasis. Subjects with signs or symptoms suggestive of brain metastasis are not eligible unless brain metastases are ruled out by computerized axial tomography (CT) scan or magnetic resonance imaging (MRI). Subjects with stable brain metastasis and those who were previously treated with radiotherapy or surgery must have no current evidence of symptomatic brain metastasis and are off steroid therapy for at least 4 weeks prior to randomization
Arms & Interventions
Arm 1
Active Comparator
0.1 mg/kg every 3 weeks
Intervention: Anti-CD137 (4-1BB) (BMS-663513) (Drug)
Arm 2
Active Comparator
1 mg/kg every 3 weeks
Intervention: Anti-CD137 (4-1BB) (BMS-663513) (Drug)
Arm 3
Active Comparator
1 mg/kg every 6 weeks
Intervention: Anti-CD137 (4-1BB) (BMS-663513) (Drug)
Arm 4
Active Comparator
5 mg/kg every 3 weeks
Intervention: Anti-CD137 (4-1BB) (BMS-663513) (Drug)
Outcomes
Primary Outcomes
Radiographic imaging, photographic and clinical evaluation will be used for tumor assessment to determine 6-month progression-free survival rate
Time Frame: every 6 weeks starting at week 12 after randomization
Secondary Outcomes
- Biomarkers(throughout the study)
- Safety profiles(throughout the study)
- Disease response rate(end of study)
- Disease control rate(end of study)
- 1-year survival(end of study)
- Pharmacokinetics(throughout the study)
- Pharmacodynamics(throughout the study)
Investigators
Study Sites (11)
Loading locations...
Similar Trials
Completed
Phase 2
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy BeforeNon-Small Cell Lung CancerNCT00870870Eli Lilly and Company64
Completed
Phase 1
Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic CancerMetastatic Colorectal CancerMetastatic Pancreatic CancerNCT03168139TME Pharma AG20
Withdrawn
Phase 2
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon CancerColonic NeoplasmsColorectal NeoplasmsNCT05456165Gritstone bio, Inc.1
Completed
Phase 1
A Study to Evaluate Biomarkers in Patients With Solid Tumors (0000-097)(COMPLETED)TumorsNCT00800865Merck Sharp & Dohme LLC36
Terminated
Phase 2
Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With LymphomaNon-Hodgkin's LymphomaNCT00510471Genitope Corporation